MedTrace Logo

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

NCT00384904 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-02-05

No results posted yet for this study

Summary

The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.

Conditions

  • HIV Infections

Interventions

DRUG

Atazanavir/Ritonavir

Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.

DRUG

Atazanavir/Ritonavir + Famotidine

Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.

DRUG

Atazanavir/Ritonavir + Famotidine

Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.

DRUG

Atazanavir/Ritonavir

Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.

DRUG

Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.

DRUG

Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine

Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384904 on ClinicalTrials.gov